執(zhí)照.jpg)
寶藿苷I
分析標(biāo)準(zhǔn)品,HPLC≥98%
Baohuoside I
CAS號：113558-15-9
分子式：C27H30O10
分子量：514.52
MDL：MFCD15071140
別名：淫羊藿次苷II; 寶藿苷 I; 寶藿苷Ⅰ; 淫羊藿次苷II
貨號 | 規(guī)格/參數(shù)/品牌 | 價(jià)格 | 貨期 |
YJ-B20075-20mg | 分析標(biāo)準(zhǔn)品,HPLC≥98% | ￥500.00 | 現(xiàn)貨 |
YJ-B20075-200mg | 分析標(biāo)準(zhǔn)品,HPLC≥98% | ￥1700.00 | 現(xiàn)貨 |
A10019-20mg | 分析標(biāo)準(zhǔn)品,含量96.0%，可溯源 | ￥1100.00 | 現(xiàn)貨 |
產(chǎn)品介紹
熔點(diǎn)：202-203℃
沸點(diǎn)：759.4℃ at 760mmHg
比旋光度：(c, 0.09 in MeOH)-121
外觀：黃色針狀結(jié)晶
溶解性：DMSO : ≥ 32 mg/mL (62.19 mM)
儲存條件：2-8℃
注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。
參考文獻(xiàn)(42篇)
42. [IF=2.5] Zheng Junzuo et al."Pharmacokinetics of seven major components in Aβ1-42-treated rats after oral administration of an aqueous extract of Curculiginis Rhizoma and Epimedii Folium."Journal of Natural Medicines.2024 Nov;:1-16
41. [IF=3.8] Jialu Shen et al."Insights into inhibitory mechanisms: Unraveling the structure-activity relationship of dietary flavonoids on gut bacterial β-glucuronidase."Journal of Functional Foods.2024 Nov;122:106510
40. [IF=2.1] Jun-Tao Sun et al."Exploring the protective effect and mechanism of icariside II on the bladder in a rat model of radiation cystitis based on transcriptome sequencing."INTERNATIONAL JOURNAL OF RADIATION BIOLOGY.
39. [IF=4.4] Chen Yangfeng et al."In Vitro evaluation of the anti-pancreatic cancer activity of epimedium herb."Frontiers in Pharmacology.2024 Jul;15:
38. [IF=6.1] Xiuchun Li et al."Icariside II alleviates lipopolysaccharide-induced acute lung injury by inhibiting lung epithelial inflammatory and immune responses mediated by neutrophil extracellular traps."LIFE SCIENCES".2024 Jun;346:122648
37. [IF=6] Dong Xie et al."Pharmacodynamic material basis and mechanism of Tenghuang Jiangu Wan on osteoarthritis using UPLC-Q-TOF-MS integrated with target network pharmacology."Arabian Journal of Chemistry".2024 Apr;17:105711
36. [IF=1.6] Liu Huimin et al."Identification and Characterization of the Chemical Constituents of Qianlie Shule Capsules by UPLC-Q-Orbitrap-MS/MS."JOURNAL OF AOAC INTERNATIONAL".2024 Feb;:
35. [IF=8.4] Ting An et al."De novo biosynthesis of anticarcinogenic icariin in engineered yeast."METABOLIC ENGINEERING.2023 Nov;80:207
34. [IF=5.4] Yi-min Liu et al."Uncovering the key pharmacodynamic material basis and possible molecular mechanism of extract of Epimedium against liver cancer through a comprehensive investigation."JOURNAL OF ETHNOPHARMACOLOGY.2023 Dec;317:116765
33. [IF=5.572] Zhen Zhao et al."An integrated strategy combining network toxicology and feature-based molecular networking for exploring hepatotoxic constituents and mechanism of Epimedii Folium-induced hepatotoxicity in vitro."FOOD AND CHEMICAL TOXICOLOGY.2023 Jun;176:
32. [IF=6.208] Jiaqi Zhang et al."The Effect of Epimedium Isopentenyl Flavonoids on the Broiler Gut Health Using Microbiomic and Metabolomic Analyses."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2023 Jan;24(8):7646
31. [IF=6.832] Li Zhang et al."Erxian herbal pair enhances bone formation in infected bone nonunion models and attenuates lipopolysaccharide-induced osteoblastinhibition by regulating miRNA-34a-5p."Bioengineered.2022;13(6):14339-14356
30. [IF=6.208] Yu Yao et al."A Novel 3-O-rhamnoside: 2″-O-xylosyltransferase Responsible for Terminal Modification of Prenylflavonol Glycosides in Epimedium pubescens Maxim.."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2022 Jan;23(24):16050
29. [IF=5.895] Fang Liu et al."Co-Immobilizing Two Glycosidases Based on Cross-Linked Enzyme Aggregates to Enhance Enzymatic Properties for Achieving High Titer Icaritin Biosynthesis."JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY.2022;XXXX(XXX):XXX-XXX
28. [IF=5.988] Li Pin et al."Epimedium koreanum Nakai–Induced Liver Injury—A Mechanistic Study Using Untargeted Metabolomics."Frontiers in Pharmacology.2022 Jul;0:2288
27. [IF=1.902] Ting Zhang et al."The influence of essential oils from ZhaLi NuSi Prescription on the pharmacokinetics of its non-volatile components in normal rats."Biomedical Chromatography. 2021 Oct 21
26. [IF=2.886] Yangyang Guo et al."Baohuoside I via mTOR Apoptotic Signaling to Inhibit Glioma Cell Growth."Cancer Manag Res. 2020; 12: 11435–11444
25. [IF=2.886] Fubiao Ni et al."Baohuoside I Inhibits the Proliferation of Pancreatic Cancer Cells via mTOR/S6K1-Caspases/Bcl2/Bax Apoptotic Signaling."Cancer Manag Res. 2019; 11: 10609–10621
24. [IF=3.645] Hongmin Zhang et al."Simultaneous determination of five isoflavones in rat plasma by LC-MS/MS: Comparative pharmacokinetic characteristics of Puerariae lobatae radix in normal and type 2 diabetic rats."J Sep Sci. 2019 Aug;42(16):2592-2601
23. [IF=3.757] Congyan Liu et al."Enhanced hydrolysis and antitumor efficacy of Epimedium flavonoids mediated by immobilized snailase on silica."Process Biochem. 2019 Nov;86:80
22. [IF=4.36] Kun Shi et al."Epimedii Folium and Curculiginis Rhizoma ameliorate lipopolysaccharides-induced cognitive impairment by regulating the TREM2 signaling pathway."J Ethnopharmacol. 2022 Feb;284:114766
21. [IF=4.411] Zhenxian Qin et al."A Widely Metabolomic Analysis Revealed Metabolic Alterations of Epimedium Pubescens Leaves at Different Growth Stages."Molecules. 2020 Jan;25(1):137
20. [IF=3.263] Jing Yang et al."Icariside II induces cell cycle arrest and differentiation via TLR8/MyD88/p38 pathway in acute myeloid leukemia cells."Eur J Pharmacol. 2019 Mar;846:12
19. [IF=6.529] Congyan Liu et al."Icariin combined with snailase shows improved intestinal hydrolysis and absorption in osteoporosis rats."Biomed Pharmacother. 2017 Oct;94:1048
18. Liu, Congyan, et al. "Icariin combined with snailase shows improved intestinal hydrolysis and absorption in osteoporosis rats." Biomedicine & Pharmacotherapy 94 (2017): 1048-1056.https:##doi.org/10.1016/j.biopha.2017.07.163
17. Yang, Jing, et al. "Icariside II induces cell cycle arrest and differentiation via TLR8/MyD88/p38 pathway in acute myeloid leukemia cells." European journal of pharmacology 846 (2019): 12-22.https:##doi.org/10.1016/j.ejphar.2018.12.026
16. 許婷,黃萌萌,李瑞云,楊茹,劉麗芳,陳彥.多基原淫羊藿不同部位質(zhì)量評價(jià)研究[J].中草藥,2020,51(01):190-196.
15. 劉聰燕,李瑞云,馬程遙,劉玉萍,瞿鼎,李曉琦,陳彥.殼聚糖交聯(lián)介孔二氧化硅固定化β-葡萄糖苷酶生物轉(zhuǎn)化淫羊藿苷研究[J].中草藥,2021,52(03):685-691.
14. 彭靜, 馬益華, 陳彥,等. 固定化蝸牛酶同時(shí)生物轉(zhuǎn)化淫羊藿中4種黃酮苷[J]. 中成藥, 2016, 38(9):1984-1990.
13. 高霞, 陳彥, 王瑩,等. 糊精濕法制粒對淫羊藿總黃酮酶解的影響[J]. 中成藥, 2014, 36(007):1392-1397.
12. 高霞, 劉璇, 陳彥,等. 淫羊藿總黃酮的生物轉(zhuǎn)化過程分析[J]. 中國中藥雜志, 2013, 38(23):4079.
11. 劉聰燕, 高霞, 陳彥,等. 淫羊藿總黃酮在骨質(zhì)疏松大鼠體內(nèi)的藥動(dòng)學(xué)行為[J]. 中成藥, 2017, 39(008):1595-1600.
10. 劉聰燕, 高霞, 黃萌萌,等. 淫羊藿總黃酮仿生酶解腸溶膠囊的制備及評價(jià)[J]. 中草藥, 2016(20).
9. 張燕. 大孔吸附樹脂分離純化淫羊藿EF5黃酮[J]. 北方藥學(xué), 2015, 000(011):11-13.
8. 劉聰燕 高霞 陳彥 等. 仿生酶解腸溶膠囊提高淫羊藿總黃酮口服生物利用度的可行性研究[J]. 中國醫(yī)藥工業(yè)雜志 2016(9期):1158-1164.
7. 王瑩 高霞 陳彥 等. 卡波姆對淫羊藿總黃酮酶解效果的影響[J]. 中國實(shí)驗(yàn)方劑學(xué)雜志 2014 20(009):1-5.
6. 楊茹 劉聰燕 許婷 等. 5種大孔吸附樹脂對淫羊藿總黃酮的吸附特性考察[J]. 中國實(shí)驗(yàn)方劑學(xué)雜志 2020 v.26(06):121-128.
5. 顧慧敏, 孫娥, 李杰,等. 炮制輔料羊脂油對寶藿苷Ⅰ-膽酸鹽自組裝膠束形成與吸收的影響[J]. 中國中藥雜志, 2019, v.44(23):133-140.
4. 劉玉萍, 丁學(xué)芳, 黃萌萌,等. 淫羊藿苷在不同骨質(zhì)疏松大鼠模型中腸道吸收代謝研究[J]. 中國中藥雜志, 2016(13):2532-2537.
3. 高霞, 陳彥, 王瑩,等. 淫羊藿苷仿生酶解過程的多因素考察[J]. 藥學(xué)學(xué)報(bào), 2013(11):1716-1721.
2. 李瑞云 劉聰燕 許婷 等. 交聯(lián)納米SiO_2固定化蝸牛酶的制備表征及轉(zhuǎn)化淫羊藿苷研究[J]. 中草藥 2019 v.50;No.655(20):57-63.
1. 楊軼舜 張彤 丁越 等. 3種淫羊藿苷次生產(chǎn)物的制備及HPLC測定[J]. 中成藥 2020 042(003):779-782.
從2011年開始我們致力于在生命科學(xué)領(lǐng)域、生物醫(yī)學(xué)實(shí)驗(yàn)技術(shù)及論文潤色服務(wù)，協(xié)助客戶各類實(shí)驗(yàn)服務(wù)及論文潤色十余年，是客戶您值得信賴的科研合作伙伴!
如果您受時(shí)間、試驗(yàn)條件等限制而無法完成您的課題研究，歡迎您與我們聯(lián)系。
實(shí)驗(yàn)技術(shù)服務(wù)：
